How GLP-1 meds are changing the way we eat and why protein snacks matter more than ever
Share
Glucagon-like peptide-1receptor agonists (GLP-1 RAs) have emerged as transformative agents in the management of type II Diabetes Mellitus and Obesity. Initially developed for glycemic control, they are now recognized for their multifaceted influence on body weight, eating behaviour, and cardiometabolic health. (1)
If you’re using GLP-1 medications like Ozempic, Wegovy or Saxenda, you’ve probably noticed some big changes, especially around food. But there’s one thing many people don’t realize: you might not be getting enough protein. (2)
Impact on Protein intake:
Given the catabolic nature of rapid weight loss, a decrease in protein intake raises concerns about lean body mass preservation. Several studies using DEXA scans have confirmed that weight loss induced by GLP-1 RAs can include reductions in fat-free mass, particularly if dietary protein intake is not adequately supported. This is especially critical for older adults or those with sarcopenia risk. Sarcopenia is a muscle disease (muscle failure) that accrue across a lifetime, common among older adult but that can also occur earlier in life. (3,4)
Behaviour and lifestyle modifications:
The GLP-1 meds significantly reduce caloric intake by increasing satiety and reducing cravings. These physiological effects translate into behavioural modifications - patients report fewer episodes of binge eating and a greater ability to resist highly palatable, energy-dense foods. (5)
Weight reduction and improved metabolic markers are associated with enhanced self-esteem, body image, and mental health outcomes. Studies revealed significant improvements in patient-reported outcomes, including quality of life and psychological well-being. (6)
People on GLP-1 meds often say they "forget to eat" or skip meals. That’s where having easy, grab-and-go options like our snacks can make a real difference in keeping your body nourished and feeling good.
Why should you eat our snacks:
Our high-protein snacks are designed for exactly this kind of nutritional gap. Whether it’s a busy morning, post-workout recovery, or simply a between-meal craving, our snacks deliver the protein your body needs, without excessive calories or sugar.
For individuals on GLP-1 therapy, adding protein-rich snacks can help balance macronutrient intake, fight muscle loss, and keep you feeling full and energized throughout the day.
GLP-1 drugs help you eat less. Oh!My help make sure you’re still eating right.
Examples of source of protein snacks:
· Pea Protein Bar with Raspberry
· Protein Bar with Deluxe Hazelnut
· Cereal Bar with Coconut
· Protein Milk Chocolate with Salted Caramel
· Raw Protein Bar with Nuts and Red Berries
· Salty Fusion Beans and Truffle
· Cocoa Coated Pea Protein Balls with Peanut Cream
Bibliography:
1. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, Schäffer L, Tang-Christensen M, Verma S, Witgen BM, Vrang N, Bjerre Knudsen L. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014 Oct;124(10):4473-88. doi: 10.1172/JCI75276. Epub 2014 Sep 9. PMID: 25202980; PMCID: PMC4215190.
2. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
3. Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, Svane MS, Bandholm T, Bojsen-Møller KN, Blond MB, Jensen JB, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021 May 6;384(18):1719-1730. doi: 10.1056/NEJMoa2028198. PMID: 33951361.
4. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. Erratum in: Age
Ageing. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046. PMID: 30312372; PMCID: PMC6322506.
5. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. PMID: 26132939.
6. Jones RA, Lawlor ER, Birch JM, Patel MI, Werneck AO, Hoare E, Griffin SJ, van Sluijs EMF, Sharp SJ, Ahern AL. The impact of adult behavioural weight management interventions on mental health: A systematic review and meta-analysis. Obes Rev. 2021 Apr;22(4):e13150. doi: 10.1111/obr.13150. Epub 2020 Oct 25. PMID: 33103340; PMCID: PMC7116866.
Author:
Sofia Silva ( CP.5784N )